Controlled application and scheduled removal of nanoparticle based chemotherapeutics (CARL) will reduce dose limiting adverse events in anticancer chemotherapy

Medical Hypotheses

Volumn 72, Issue 4, 2009, Pages 393-397

  Pütz, Gerhard ^a   Schmah, Oliver ^a   Eckes, Jürgen ^b   Hug, Martin J ^a   Winkler, Karl ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TellTargeting Medical GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; NANOPARTICLE; NEW DRUG;

APHERESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG QUALITY; DRUG SAFETY; DRUG TARGETING; HEMODIALYSIS; HUMAN; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 60749109759     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.11.027     Document Type: Article

References (24)

1. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36 (2000) 11-14
2. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. N Engl J Med 332 14 (1995) 901-906
3. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
4. Gabizon A., Shmeeda H., and Barenholz Y. Pharmakokinetics of pegylated liposomal doxorubicin. Clin Pharmakokinet 42 5 (2003) 419-436
5. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 4 (1999) 692-743
6. Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., and Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 18 (2007) 1159-1164
7. Lyass O., Uziely B., Ben-Yosef R., Tsemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 89 (2000) 10-47
8. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
9. Harrington K.J., Mohammadtaghi S., Uster P.S., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7 (2001) 243-254
10. Northfelt D.W., Martin F.J., Working P., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmakokinetics, tumor localization, and safety in patients with AIDS-related kaposi sarcoma. J Clin Pharmacol 36 (1996) 55-63
11. Charrois G.J.R., and Allen T.M. Multiple injections of pegylated liposomal doxorubicin: pharmakokinetics and therapeutic activity. J Pharmacol Exp Ther 306 3 (2003) 1058-1067
12. Bosch T. Therapeutic apheresis-state of the art in the year 2005. Ther Apher 9 6 (2005) 459-468
13. Malchesky P.S., Koo A.P., Roberson G.A., Hadsell A.T., and Rybicki L.A. Apheresis technologies and clinical applications, the 2002 international apheresis registry. Ther Apher 8 2 (2004) 124-143
14. Pütz G., Eckes J., Schmah O., Winkler K., and Wieland H. Elimination of liposomes by different separation principles used in LDL-apheresis. Ther Apher 12 1 (2008) 2-12
15. Lim H.J., Masin D., McIntosh N.L., Madden T.D., and Bally M.B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292 1 (2000) 337-345
16. Vaage J., Donovan D., Uster P., and Working P. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Brit J Cancer 75 4 (1997) 482-486
17. Koukourakis M.I., Koukouraki S., Giatromanolaki A., et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas. Acta Oncol 39 2 (2000) 207-211
18. Koukourakis M.I., Koukouraki S., Fezoulidis I., et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Brit J Cancer 83 10 (2000) 1281-1286
19. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
20. Uziely B., Jeffers S., Isacson R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I: studies. J Clin Oncol 13 (1995) 1777-1785
21. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. The Oncologist 10 (2005) 205-214
22. Alberts D.S., Muggia F.M., Carmichael J., et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31 Suppl. 13 (2004) 53-90
23. Jensen S.S., Andresen T.L., Davidsen J., Hoyrup P., Shnyder S.D., Bibby M.C., et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 3 11 (2004) 1451-1458
24. Kong G., Anyarambhatla G., Petros W.P., et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60 (2000) 6950-6957